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Primary Prevention of Alzheimer’s 
Disease (AD)
Ettore Bergamini and Gabriella Cavallini
Abstract
Alzheimer dementia (AD) is a complex, aging-associated disease whose effects 
on the brain (an organ made up by nonreplaceable cells) are devastating. Disease is 
not curable, but progress in pathobiology shows that intervention on aging can make 
primary prevention of AD feasible. According to the amyloid-cascade hypothesis, 
mechanisms of AD include: an age-related alteration of free radical metabolism in 
membranes, leading to a higher yield in the toxic Aβ1-42 peptide and an overwhelm-
ing impact on the weaker repair mechanisms of the aging cells. The proposed inter-
vention on aging with anti-AD effects includes a daily assumption of antioxidants 
(red wine polyphenols enriched with resveratrol), a reinforcement of membrane 
antioxidant defenses by the assumption of polyunsaturated fatty acids at the first 
meal after fasting, and an enhancement of cell repair function (at the proteasome 
and autophagy level by an intermittent feeding regimen and physical exercise plus 
the assumption of antilipolytic agents during time of fasting). The beneficial effects 
of diet and physical activity on the endogenous production of protective nerve 
growth factors are magnified by an enriched environment. Treatment has already 
been started on healthy individuals at a higher risk of AD in the city of Volterra.
Keywords: Alzheimer’s disease, proteasome, autophagy, antioxidants, PUFAs, APP, 
cholesterol, antilipolytic drugs, calorie restriction, physical exercise, brain plasticity, 
nerve growth factors
1. Introduction
Like many other degenerative diseases, AD is an irreversible and progressive 
cerebropathy, the cause of one of the most common types of dementia affecting 
the elderly. It is a brain disorder characterized by the accumulation of two main 
protein aggregates, senile plaques and neurofibrillary tangles, leading to a progres-
sive neuronal degeneration. It causes death after years of disability, progressive 
loss of memory, inability to perform normal daily activities, and, finally, dementia. 
The senile plaques are generated by the deposition in human brain of fibrils of the 
β-amyloid peptide (Aβ), a fragment derived from the proteolytic processing of the 
amyloid precursor protein (APP). There is evidence that oxidative stress might be 
the main factor that turns APP into a proteolytically processable substrate. The 
neurofibrillary tangles (NFTs) are seen as a compact filamentous network formed 
by paired helical filaments (PHFs), whose major component is a hyperphosphory-
lated Tau protein. Two main protein kinases appear to be involved in the anomalous 
tau phosphorylation: the cyclin-dependent kinase Cdk5 and glycogen synthase 
kinase GSK3. Dysfunction of the ubiquitin-proteasome system may be the cause [1] 
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possibly together with a secondary failure of the engulfed lysosomal degradation 
resulting in apoptosis. Pathology is a consequence of the extensive neuronal death, 
and when it manifests clinically, it is already incurable. Human, social, and health 
costs of this incurable disease are immense. It is highly desirable indeed an effective 
primary prevention to postpone the appearance of the debilitating manifestations, 
hopefully to the time of death.
2.  Biological aging: Is it a major risk or the basic causative factor for 
neurodegeneration?
Age is the main factor in major debilitating and life-threatening conditions, 
including cancer, cardiovascular disease, diabetes, and neurodegeneration, all 
of which are therefore increasing in prevalence [2]. Nowadays almost all can 
make it to the old and nobody can say anymore that reaching old age is a fortune, 
and between those who should solve social and health problems of older people 
prevails the old slogan “old age is not a disease.” For many scholars, however, 
modern scientific discoveries confirm the deductions of ancient philosophers: all 
living beings, without exception, would be affected by an innate chronic degenera-
tive disease, we call it aging, characterized by having an incubation period as long 
as be compatible with the reproductive success of the species. If aging is a disease 
and not a simple disability and disease risk factor, it is not surprising that the 
diseases associated with it (cancer, neurodegeneration, atherosclerosis, diabetes, 
etc.) can be regarded as signs or easily preventable complications, all together, by 
fighting the underlying disease. The prescription is simple but hard to follow a 
sober physically active lifestyle; to eat fruits, vegetables, fish, and little red meat; 
to take food after having been hungry for a few hours; to take supplements rich 
in polyunsaturated fatty acids (PUFAs) after dinner regularly; and to make good 
use of all functions of all organs of our body, including brain. This is exactly what 
cardiologists, diabetologists, oncologists, and neurologists all recommend for 
primary prevention. Understanding exactly the causes of aging and of all age-
associated diseases may help to tackle the growing problem of neurodegeneration. 
Free radicals are the root of all evil. They may be generated either by endogenous 
(metabolic) causes or by environmental factors, including pollution (living less 
than 50 m from a major traffic road may increase hazards ratio of incident demen-
tia by a 10% [3] and even oral hygiene and chronic inflammation [4]). Perhaps, 
we should remind here the oxygen paradox: without oxygen we die in minutes; 
with oxygen we grow old and die [5]. Oxygen is actually slowly poisonous, and 
it just takes 75–100 years to kill us, difference depending on how much we use 
and how we deal with it and repair the endogenous oxidative damage to protein, 
lipids, and (most important) DNA responsible for intrinsic aging, as well as the 
additional free radical-mediated damage from the inflammatory responses and 
environmental factors (e.g., ionizing radiation) [6]. It was computed that the 
oxygen consumption of human brain may be higher than 3 mL (i.e., about 1020 
oxygen molecules)/g/min. In humans, over 99% of these molecules do generate 
water safely, but 1018 per min will produce free radicals, approximately 106 free 
radicals per cell per min. It was estimated that the number of oxidative hits to DNA 
in the human cell per day is about 10,000 and that DNA-repair enzymes efficiently 
remove 99.9% of the lesions formed so that only one oxidative lesion accumulate 
in the DNA of any cell every day. This is not nothing: it makes over 30,000 lesions 
in a long life [7]. Since there are about 20,000 genes in human cells, by the age of 
100 years, all neurons may carry about two mutations a gene on the average. Why 
be surprised if over time cell functions are reduced?
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3. Pathology of AD
With AD patients, the brain is smaller than normal and of reduced weight. A 
reduction of the thickness of the convolutions is evident. Atrophy is more evident in 
the temporal lobe, particularly in the parahippocampus, but also in the frontal and 
parietal regions. The occipital lobe and the motor cortex may be spared. Histologically, 
several major changes are recognized in AD. Amyloid, consisting of accumulations 
of Aβ peptide, is deposed in the cerebral cortex in the form of spherical deposits 
called senile plaques. Intraneuronal inclusions are formed in the cortical neurons, 
constituted by abnormal, often flame-shaped, bundles of filaments called neurofibril-
lary tangles, which occupy a large part of the neuronal cytoplasm, and are made up 
of a protein that binds to the microtubules, called tau protein. The processes of the 
cortical nerve cells diverge, twist, and dilate due to the accumulation of filaments in 
the form of tangles [8]. Changes are due to oxidative stress damage and to the relative 
failure of repair mechanisms at the molecular and subcellular (autophagy) level and 
result in the disruption of the neural network (Table 1). It is customary to distinguish 
two forms of AD. There is indeed a precocious rare form that occurs between 30 and 
60 years, with a peak in the fifties, with a formation of the amyloidogenic peptide Aβ 
(1-42) from APP genetically favored by particular isoforms of presenilin 1 and 2 or of 
APP. The other form, sporadic, more frequent, late-onset (observed after age 65 with a 
frequency that increases with age) is due to the progressive increase in oxidative stress 
and decline with increasing age in mitochondrial and peroxisomal maintenance and in 
the efficiency of the mechanisms that neutralize free radicals and repair damage. This 
latter form might be postponed successfully to time of death by anti-aging interven-
tions (nutrition, physical activity, damage repair, nerve growth factors).
4.  The primary cause of AD and the roles of cholesterol and unsaturated 
fatty acids
It is obvious that native APP cannot be the ultimate substrate for γ-secretase 
trimming. Hence, both with the earlier and the later form of AD, the rate of Aβ 
Mechanism of repair Effects of the age-related decline
Molecular level
DNA repair
Proteasome
Phospholipid repair
Accumulation of DNA lesion
Accumulation of altered proteins
Changes in polyunsaturated fatty acids
Subcellular Level
Autophagy and lysosomal function Accumulation of altered mitochondria
Accumulation of protein aggregates
Changes in membrane proteins and lipids
Cellular and tissue level
Apoptosis Accumulation of damaged, misfunctional cells in all tissues
There is evidence that the above-mentioned repair mechanisms are responsible for cleaning cells from any produced 
waste and for getting tissues rid of irreversibly altered cells. In younger persons, functions are redundant but 
progressively decline with increasing age, and may gradually fail in older persons resulting in the accumulation of 
“waste” in cells and tissues. On a healthy life, “waste” is the limiting factor for cell and tissue “cleaning” activities, 
but waste recognition-acuity co-varies with cell and body request for nutrients and repair. Function of all repair 
mechanisms are inducible (or suppressible) depending on life style. Benefits from healthy life style, diet restriction, 
and physical activity depend at least in part from the induction of repair mechanisms.
Table 1. 
Effects of failure of repair mechanisms at the molecular, subcellular, and cellular level.
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production from APP should depend on a higher production of the ultimate sub-
strate, possibly by a posttranslational modification of the APP molecules, likely to 
be secondary to oxidative stress. Age-related changes in the machinery that protects 
membrane proteins from free radical-mediated injury might help to account for age 
dependency [9]. With regard to the higher production of Aβ (1-42) in AD patients, 
a displacement of the free radical-mediated attack from the wanted site in the APP 
molecule might account for the higher involvement of the β and γ secretase path-
ways and the higher yield in Aβ 1-42. The effect may be favored either by genetic 
factors and/or aging.
4.1 Role of cholesterol
Elevated cholesterol levels may be associated with a higher risk of AD [10]. 
Evidence was found suggesting an intimate connection between APP processing 
and lipid rafts [11]. An age-related increase in cholesterol and oxidized cholesterol 
products (namely 24-hydroxycholesterol and 27-hydroxycholesterol) was shown 
indeed to be increasingly associated with AD progression (brain levels are higher 
in AD patients, and levels of 24-hydroxycholesterol, 27-hydroxycholesterol and 
cholesterol in the cerebrospinal fluid appear to be useful biomarkers for the evalu-
ation of mild cognitive impairment (MCI) and AD, together with Aβ42, total tau, 
and phospho-tau) [12]. It has been shown recently that higher total cholesterol 
levels in the blood are observed long before the clinical manifestation of MCI and 
AD in patients without psychiatric or somatic comorbidities and are independent of 
APOE genotype [13]. However, evidence was produced that changes in cholesterol 
metabolism in AD may not be the primary cause of the disease (see below): they 
may simply be a tightly associated sign with Aβ production by sharing a common 
cause (a higher intramembrane oxidative stress) (see below).
4.2 Role of polyunsaturated fatty acids (PUFAs)
PUFAs and their oxylipins may affect the onset of AD [14]. The administration 
of omega-3 fatty acids may cause a dose-dependent reduction of triglyceridemia 
and cholesterolemia and exert an antiatherogenic effect [15]. With regard to 
mechanisms, in view of the proposed protective role of unsaturated fatty acids in 
phospholipids against the free radical-mediated injury of membrane proteins [9], 
it should be mentioned that the distribution of unsaturation (the trap for unpaired 
electrons) across the membrane leaflets is not uniform, and minima (the least 
protected areas from oxidative stress) were observed close to the C-6 site (i.e., very 
close to the membrane exterior, to the phosphorylable site of HMGCoAR, and to 
the vulnerable site of APP) and at the C-15 and C-17 levels (closer to the free radical 
conductor dolichol) [16]. Quite interestingly, signal might help focus free radical-
mediated injury on the right target; more interestingly, in ad-libitum-fed (shorter-
lived) rats, is its recognizability that may fade on aging: the abundancy of double 
bonds near the C-6 site (but not at the C-15 and C-17) indeed appears to increase up 
to a doubling by age 24 months. Furthermore, this age-related change is prevented 
in part by nutritional anti-aging intervention [17]. Perhaps age-related changes in 
the production of Aβ1-42, in the activity of HMGCoA reductase, and in the PUFA 
content of membrane phospholipids are all somehow bound together and involved 
all in the risk of AD. As an additional comment, beneficial intervention on Aβ1-42 
production may require the administration of antioxidants (e.g., polyphenols and 
resveratrol) to curb oxidative stress and of omega-3 fatty acids at a high dosage at 
the first good meal after fast (on the anabolic phase of metabolism) to counteract 
age-related changes in phospholipid unsaturated fatty acids and increase membrane 
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resistance to oxidative stress. An enhancement of the membrane turnover rate 
may be useful (e.g., by dietary restriction and/or pharmacological stimulation of 
autophagy) [18].
5. The pathogenesis of AD
The hypothesis of the amyloid cascade attributes to beta-amyloid, the respon-
sibility of all cases of AD, and considers the tau pathology and other degenerative 
changes secondary to the Aβ pathology. Indeed, the extracellular accumulation 
of Aβ, a hallmark of AD, produces ROS, including hydrogen peroxide (H2O2) in 
the presence of Fe3+or Cu2+ [19, 20]. The amyloid β-peptide responsible for AD is 
generated within the transmembrane domain (TMD) of a C-terminal fragment 
of the amyloid β protein-precursor (APP CTFβ) by the proteolytic action of the 
γ-secretase complex [21]. Very interestingly, it was shown that some mutation(s) 
that promote destabilization of TMD helix might affect the length of the accu-
mulated Aβ species and the ratio of the toxic Aβ42 to the safer Aβ40 peptide and 
may result in a young-onset AD [22]. Hence, the speculation may be invited that a 
free radical-induced modification in (some) amino acids of APP close to the C-6 
carbon of phospholipid fatty acids might have a similar effect and enhance amyloid 
deposition. With regard to disease progression, many different active factors in 
sequence would determine timing of neuronal damage and symptom development, 
such as: (1) an overproduction of the toxic Aβ peptide (1-42) for genetic reasons 
and/or decrease in the quality of the antioxidant device of the membranes, (2) an 
ensuing increase in Aβ excretion in the oligomeric form may concentrate the redox-
active copper at neuronal membranes before stacking in amyloid fibrils to form an 
ROS generating complex, (3) oxidative stress may be enhanced with an ensuing 
increase in lipid peroxidation and di-tyrosine formation, and (4) inflammation 
and activation of the microglia, which may further increase free radical generation, 
spread lytic enzymes, and cause cytotoxicity and anticipation of apoptotic neuro-
nal death [23].
6. AD-associated changes in cholesterol metabolism
Abnormal cholesterol metabolism is an established feature of AD: levels of 
cholesterol are increased in MCI subjects and levels of 24-hydroxycholesterol and 
27-hydroxycholesterol are elevated compared to controls both in AD and MCI sub-
jects [24]. It appears that the rate of cholesterol production may be boosted by a free 
radical attack via a constitutive activation of HMGCoA-reductase, the rate-limiting 
step in sterol biosynthesis. Mechanism was clarified by Bergamini group in Pisa in 
cooperation with Trentalance group in Rome: in the rat, a free radical attack may 
prevent AMP-dependent protein kinase from phosphorylating a serine residue close 
to the C-terminus of HMGCoA reductase, Ser 872 with human enzyme [25, 26]. It 
has been proposed by several authors that higher cholesterol may disturb the lipid 
raft domains in various membrane organelles and affect the functioning of α, β, and 
γ secretases as well as APP itself and the production of Aβ 42; and that by converse, 
the toxicity of Aβ may be produced, in part, by disturbing the composition of the 
lipid raft domains in which they reside [27, 28]. Both with in vitro experiments and 
with animal models, statins strongly lowered blood cholesterol and reduced the 
levels of Aβ peptides, Aβ 42 and A β40 [29, 30]. However, a statistically significant 
correlation between two events does not necessarily imply the existence of a causal 
link: an alternative explanation is that the events share a common cause. This might 
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be the case here: aging is known to lower antioxidant defenses, and any increase in 
oxidative stress either in vitro (e.g., by UV radiation of isolated rat liver cells) or 
in vivo (by chronic deprivation either of vitamin E or PUFA) may cause the consti-
tutive increase in HMGCoA reductase and deregulate cholesterol synthesis [26, 31].
7. Alzheimer’s disease: treatment or prevention strategies?
The pharmacological treatments for AD can be divided into two categories: 
symptomatic treatments such as acetylcholinesterase inhibitors and N-methyl-
D-aspartate (NMDA) receptor antagonists and etiology-based treatments such as 
secretase inhibitors, amyloid binders, and tau therapies [32].
Despite significant investments in therapeutic drug discovery programs, 
no drugs to alter the course of disease have been found so far. Only four drugs 
with cholinergic (donepezil, galantamine, rivastigmine) or glutamatergic activ-
ity (Memantine) are currently approved and marketed for the treatment of 
AD-associated dementia, and their utility is very limited; several trials on inhibitors 
of γ-secretase and β-secretase have been discontinued; the available drug treat-
ments of AD are merely symptomatic and unsatisfactory, and only minor benefits 
are obtained even if therapy is started at a very early time [33]. By the way, the 
physiological function of the amyloidogenic peptide has not been clarified yet, 
though it may be synchronized with life history [34].
In conclusion, no effective therapy is available to cure AD so far, and attention 
had to be shifted to the primary prevention of the disease. It was realized indeed 
that there is an extremely long, symptom-free prodromal phase in the path toward 
dementia in which deficits in synaptic density and plasticity are the principal altera-
tion [35]. As an additional comment, better diagnostic tools and earlier diagnosis 
are needed (earlier timing is an important factor for the success rate of interven-
tion), and novel strategies toward primary intervention may be wanted [36].
Problems in primary prevention were tackled recently. Qiu et al. [37] stressed 
the potential risk roles of vascular risk factors and disorders (e.g., cigarette smok-
ing, midlife high blood pressure and obesity, diabetes, and cerebrovascular lesions) 
and the possible beneficial roles of psychosocial factors (e.g., high education, 
active social engagement, physical exercise, and mentally stimulating activity) in 
the pathogenetic process and clinical manifestation of the dementing disorders. 
Paillard-Borg et al. [38] showed that the participation in activities (mental, physi-
cal, or social activity) can retard the onset of dementia significantly (a 17 months’ 
delay was seen in mean age at dementia onset between an inactive group and the 
most active group).
It may be worthwhile to remind here that the primary risk factor for AD is old 
age and that the prevalence of AD and other age-related dementias increases with 
increasing age [2]. It is very surprising, indeed, that little attention has been given so 
far to benefits from the most effective antiaging interventions (dietary restriction 
and physical activity) on the age of onset of neurodegeneration [39].
Antiaging diet restriction is known to be the most effective intervention that 
retards aging and extends lifespan and health span. Effects are known to involve the 
activation of macroautophagy, a cell repair mechanism [40] that can be intensified 
by the administration of antilipolytic agents during fasting to safely improve cell 
housekeeping and boost the benefits of caloric restriction [41]. Physical exercise, 
which is available at low cost and largely free of adverse effects, is another powerful 
antiaging strategy that can influence, at least partly, most of the hallmarks of bio-
logical aging [42]. It is known that greater levels of physical activity are associated 
with decreased risk of a future diagnosis of MCI or AD [43], extend longevity, and 
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reduce the risk of physical disability and may be an important adjunct to pharmaco-
logical treatment of AD [44].
Looking at mechanisms, it appears that dietary restriction and physical exer-
cise share common neuroprotective mechanisms and should be included both in 
primary prevention of AD to increase the quality of nerve cells and oppose neu-
rodegeneration and apoptosis (the third item in the Table 1, a repair mechanism 
harmful to brain) and give synergic support in a “train body and brain” program 
aimed to enhance neurotrophic antiapoptotic signals and defer or suppress neuron 
misfunctioning and death [45].
Antiaging diet restriction improves metabolism and promotes rejuvenation (by 
stimulating autophagy) of visceral organs that talk to brain via the vagus nerve and 
spinal afferent nerves [46]. Physical exercise improves metabolism and promotes 
rejuvenation of the lean body mass by the process of autophagy, which is very active 
in skeletal muscle and more intense when strenuous exercise is performed in the 
fasted state [47] and helps communication of the exercising muscle with the brain 
via increase in the discharge frequency of thinly myelinated (Group III) and unmy-
elinated (Group IV) nerve fibers [48]. Under these conditions, physical exercise 
is good both for physical health and mental health and abilities, and constitutes a 
practical neuroprotective strategy that provides a remarkable protection against 
brain insults of different etiology and anatomy [49].
Quite interesting, it has been clarified that dietary restriction and physical 
exercise share also common neuroprotective metabolic mechanism: the increased 
availability to brain of 3-hydroxybutyrate and an ensuing endogenous production 
of the brain-derived-neurotrophic-factor BDNF [50], and thus, both shelter the 
aging brain from memory loss and neurodegeneration, ameliorate mitochondrial 
function, and reduce the expression of apoptotic and inflammatory mediators 
[51]. As an additional evidence: both treatments safely modulate the endogenous 
production of BDNF, a neurotrophin that is vital to the survival, growth, and 
maintenance of neurons in key brain circuits involved in emotional and cognitive 
function [52, 53]. As an additional benefit, sustained levels of physical exercise 
together with dietary intervention may increase brain uptake of physiologically 
relevant neuroprotective trophic factors, such as IGF-I [49].
In conclusion, both (dietary and physical) interventions should be included 
in primary prevention of AD to increase quality of nerve cells and oppose neuro-
degeneration and apoptosis to implement reported programs aimed to enhance 
neurotrophic antiapoptotic signals and defer or suppress neuron misfunctioning 
and death.
8.  The “train body and brain” protocol for a primary intervention on AD 
in the city of Volterra (Tuscany, Italy)
In view of the continuing increase in the prevalence of dementia to a magnitude 
growing to emergency [54, 55], a free of charge program to train people at higher 
risk of disease has been started in the Italian city of Volterra. Since AD is an aging-
associated multifaceted disease that is hard to treat by single-modal treatment, 
a corresponding multifaceted preventive approach was included in a teaching 
program on how to counteract in practice the effects of biological and pathological 
aging on human body and brain.
Program includes activation of the global antioxidant defense system in order 
to attenuate the AD-causative oxidative stress, improvement of the function of the 
free radical conducting mechanism responsible for membrane resistance to oxida-
tive stress, reinforcement of cell repair mechanisms at the molecular and subcellular 
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level by dietary and physical intervention, and targeted high-intensity training 
of cognitive brain functions to boost the induction of neurotrophic factors by the 
physiological mechanism. Here, a few details on protocol are given.
a. Strengthening antioxidant defenses by nutritional intervention. It is said that 
the efficiency of antioxidant defenses may be boosted by eating the colors in 
the peel of fruits and vegetables that are known to contain complex mixtures 
of polyphenols and other phytochemicals. (e.g., polyphenols in blueberries 
and red grapes and wine [56]; epigallocatechin-3-gallate in green tea [57]; 
total phenolic, flavonoids, and flavonols in pomegranate [58, 59]). Red wine is 
particularly rich in specific polyphenolic compounds that appear to affect the 
biological processes of AD and Parkinson’s disease, such as quercetin, myrice-
tin, catechins, tannins, anthocyanidins, resveratrol, and ferulic acid. Indeed, 
there is now a consistent body of in vitro and in vivo data on the neuroprotec-
tive activity of red wine polyphenols [60], and it is known that effects may 
be boosted by adding more resveratrol [61]. Obviously, to enjoy optimum 
benefits, participants are taught to assume phytochemicals in a way to ensure 
protection throughout the day.
b. Increasing the resistance of cell membranes to oxidative stress. In order to get 
a better resistance to ROS-induced damage to brain and prevent from neuro-
degeneration and neuronal apoptosis, participants are instructed to a timed 
assumption of omega-3-rich fish oil. PUFAs are essential to control oxidative 
damage to neurons [62] when they are incorporated in the phospholipid mol-
ecules as a part in the proposed antioxidant machinery that protects membrane 
proteins from peroxidation (Figure 1) (On the contrary, free PUFAs are very 
sensitive to a free radical attack and ready to peroxidation.) To get full benefit 
from supplement, participants are requested to take pills at the first good meal 
after the long time of fasting, when chances to be incorporated in membrane 
phospholipids are paramount [63].
Figure 1. 
Model of the membrane antioxidant machinery based on the proposed locations of dolichol (disc, green), 
ubiquinone (hexagon, red), and vitamin E (rhomb, pink) (see Cathcart et al. [69]; Sharma et al. [70]).
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c. Promoting cell cleaning and rejuvenation. It is done by teaching participants 
in practice how to eat a healthy calorie-restricted diet and to make aerobic 
physical exercise during fasting. It is known indeed that calorie restriction is 
the most robust antiaging intervention known so far [64], and that benefit 
comes from the alternation of a long time of fasting and good meal (twice 
a week, participants spend a great part of their time in a state of fasting) 
[65] in order to get cells free of altered ROS-hypergenerating organelles 
in older cells [66, 67]. Good maintenance will be finalized later, thanks to 
a good meal. If needed, benefit might be magnified by taking a pill of an 
antilipolytic drug on the time of fasting [41]. Benefits of protocol might be 
monitored noninvasively by the assay of the urinary excretion of 8-hydroxy-
2′-deoxyguanosine, a recently recommended biomarker for monitoring 
oxidative status over time [68].
d. A targeted high-intensity training of cognitive brain functions. In addition to 
the previously described interventions on diet and physical activity, the mental 
and the social activity protocols tested by Paillard-Borg et al. [38] are being 
practiced. In view of the results obtained by Dahlgren et al. [51], high intensity 
interval training (HIIT) and memory training using the PEAK brain training 
app are included in the protocol.
9. Conclusion
A dynamic antiaging nutritional and physical intervention protocol including 
enriched living conditions is described useful to prevent the appearance of aging-
associated AD. Treatment is already granted for free to the citizens of the city of 
Volterra known to be at higher risk of AD (relatives of AD patients and persons 
with mild cognitive impairment, likely to progress to clinically probable AD at a 
considerably accelerated rate compared with healthy age-matched individuals) 
to teach them how to counteract and retard the disease. Treatment was designed 
to delay biological aging and empower adult brain plasticity in order to retard the 
progress of brain aging and associated diseases. It includes a daily assumption of 
antioxidants (red wine polyphenols enriched with resveratrol), a reinforcement of 
membrane antioxidant defenses by the timed assumption of polyunsaturated fatty 
acids, and an enhancement of cell repair function at the molecular and subcellular 
level by an intermittent feeding regimen and physical exercise, whose efficiency is 
empowered by the pharmacological intensification of autophagy by an antilipolytic 
drug (Acipimox) taken at a very low dosage while fasting. The beneficial effects on 
neurodegeneration are magnified by living an enriched environment. The effective-
ness of the treatment will be detected by comparison with the expected frequencies 
of disease appearance.
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